Replies to post #27137 on Amarantus Bioscience Holdings Inc (AMBS)

[barbershop]

Gipper check this out. As recent as 2007, Genzyme entered into a $150 million partnership with Ceregene to gain access to ex-U.S. marketing rights Neurturin after Ceregene successfully completed ONLY A Phase 1 clinical study demonstrating safety for Neurturin as a gene therapy product.